Dianthus Therapeutics (NASDAQ:DNTH) Given New $36.00 Price Target at Wedbush

Dianthus Therapeutics (NASDAQ:DNTH) had its price target reduced by Wedbush from $38.00 to $36.00 in a research note issued to investors on Friday, Benzinga reports. They currently have an outperform rating on the stock.

Several other equities research analysts have also recently weighed in on the company. HC Wainwright began coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They issued a buy rating and a $40.00 price objective for the company. Lifesci Capital upgraded shares of Dianthus Therapeutics to a strong-buy rating in a report on Tuesday, June 11th. Cantor Fitzgerald started coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They issued an overweight rating for the company. Robert W. Baird initiated coverage on shares of Dianthus Therapeutics in a research note on Friday, July 26th. They set an outperform rating and a $58.00 target price on the stock. Finally, Baird R W raised shares of Dianthus Therapeutics to a strong-buy rating in a research note on Friday, July 26th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Dianthus Therapeutics presently has an average rating of Buy and a consensus target price of $44.71.

Dianthus Therapeutics Price Performance

DNTH traded up $0.76 during trading on Friday, hitting $27.50. 145,393 shares of the stock traded hands, compared to its average volume of 194,359. The firm has a 50-day moving average of $26.34 and a 200 day moving average of $25.05. Dianthus Therapeutics has a 12-month low of $6.58 and a 12-month high of $33.77. The firm has a market capitalization of $807.10 million, a P/E ratio of -4.72 and a beta of 1.89.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The firm had revenue of $0.87 million for the quarter, compared to the consensus estimate of $0.48 million. As a group, equities analysts predict that Dianthus Therapeutics will post -2.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Tower Research Capital LLC TRC bought a new position in Dianthus Therapeutics during the 4th quarter valued at approximately $25,000. SG Americas Securities LLC bought a new position in shares of Dianthus Therapeutics during the second quarter valued at $112,000. WINTON GROUP Ltd purchased a new position in shares of Dianthus Therapeutics in the 2nd quarter worth about $265,000. Virtu Financial LLC bought a new position in Dianthus Therapeutics in the 1st quarter worth about $390,000. Finally, Hussman Strategic Advisors Inc. purchased a new stake in Dianthus Therapeutics during the 1st quarter valued at about $630,000. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.